Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 7/20 | 0.87 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.87 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.87 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.87 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.87 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.87 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.87 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.87 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.87 |
| ▸ | RECQL | P46063 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | GMNN | O75496 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bendamustine SCHEMBL26319 | 0.93 | HDAC6 (1.00) | HDAC6HDAC1HDAC3HDAC4HDAC2 | |
| Bendamustine SCHEMBL9950832 | 0.93 | HDAC6 (1.00) | HDAC6HDAC1HDAC3HDAC4HDAC2 | |
| Bendamustine SCHEMBL29394147 | 0.93 | HDAC6 (1.00) | HDAC6HDAC1HDAC3HDAC4HDAC2 | |
| Bendamustine SCHEMBL29352819 | 0.92 | HDAC6 (0.98) | HDAC6HDAC1HDAC3HDAC4HDAC2 | |
| Bendamustine SCHEMBL18843 | 0.92 | HDAC6 (0.98) | HDAC6HDAC1HDAC3HDAC4HDAC2 | |
| SCHEMBL16772708 | 0.92 | HDAC6 (0.94) | HDAC6HDAC1HDAC3HDAC4HDAC2 | |
| Bendamustine SCHEMBL15523734 | 0.92 | HDAC6 (0.98) | HDAC6HDAC1HDAC3HDAC4HDAC2 | |
| Bendamustine SCHEMBL12497247 | 0.92 | HDAC6 (0.98) | HDAC6HDAC1HDAC3HDAC4HDAC2 | |
| SCHEMBL14816587 | 0.91 | HDAC6 (0.92) | HDAC6HDAC1HDAC3HDAC4HDAC2 | |
| Bendamustine SCHEMBL118499 | 0.91 | HDAC6 (0.96) | HDAC6HDAC1HDAC3HDAC4HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10294208-B2 | Bendamustine derivatives and related compounds, and medical use thereof in cancer therapy | SYNBIAS PHARMA AG (CH) | 2019-05-21 | — | — | US | disclosed |
| US-20170313663-A1 | Bendamustine Derivatives and Related Compounds, and Medical Use Thereof in Cancer Therapy | Schickaneder, Helmut (DE) | 2017-11-02 | — | — | US | disclosed |
| US-20170313663-A1 | Bendamustine Derivatives and Related Compounds, and Medical Use Thereof in Cancer Therapy | Schickaneder, Helmut (DE) | 2017-11-02 | — | — | US | disclosed |
| US-9096627-B2 | Hydroxamic acid derivatives | PURDUE PHARMACEUTICAL PRODUCTS L.P. (US) | 2015-08-04 | — | — | US | disclosed |
| WO-2015091827-A1 | BENDAMUSTINE DERIVATIVES AND RELATED COMPOUNDS | SCHICKANEDER HELMUT (DE) | 2015-06-25 | — | — | WO | disclosed |
| US-20150152066-A1 | BENDAMUSTINE DERIVATIVES AND RELATED COMPOUNDS, AND MEDICAL USE THEREOF IN CANCER THERAPY | HELMUT SCHICKANEDER (DE) | 2015-06-04 | — | — | US | disclosed |
| US-20150152066-A1 | BENDAMUSTINE DERIVATIVES AND RELATED COMPOUNDS, AND MEDICAL USE THEREOF IN CANCER THERAPY | HELMUT SCHICKANEDER (DE) | 2015-06-04 | — | — | US | disclosed |
| US-20140066419-A1 | HYDROXAMIC ACID DERIVATIVES | PURDUE PHARMACEUTICAL PRODUCTS L.P. (US) | 2014-03-06 | — | — | US | disclosed |
| US-20110269706-A1 | Hydroxamic Acid Derivatives | NORTHLAKE BIOSCIENCES LLC (US) | 2011-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140066419-A1 | HYDROXAMIC ACID DERIVATIVES | HDAC5, HDAC7, HDAC4 | HDAC6 7/4885HDAC1 4/4885HDAC3 10/4885 |
| US-20150152066-A1 | BENDAMUSTINE DERIVATIVES AND RELATED COMPOUNDS, AND MEDICAL USE THEREOF IN CANCER THERAPY | FLT4, FLT3, FLT1 | HDAC6 985/4885HDAC1 3165/4885HDAC3 3630/4885 |
| US-10294208-B2 | Bendamustine derivatives and related compounds, and medical use thereof in cancer therapy | FLT4, FLT3, FLT1 | HDAC6 985/4885HDAC1 3165/4885HDAC3 3630/4885 |
| US-20110269706-A1 | Hydroxamic Acid Derivatives | CD74, HLA-DRB1, HDAC5 | HDAC6 12/4885HDAC1 7/4885HDAC3 29/4885 |
| US-20170313663-A1 | Bendamustine Derivatives and Related Compounds, and Medical Use Thereof in Cancer Therapy | FLT4, FLT3, FLT1 | HDAC6 985/4885HDAC1 3165/4885HDAC3 3630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.